• Qui Tam
  • SEC
  • CFTC
  • FCPA
  • Whistleblower Resources
  • FAQS
Subscribe
Donate
No Result
View All Result
Whistleblower Network News
The Truth at Any Cost.
Qui Tam, Compliance and Anti-Corruption News.
SIGN THE PETITION FOR NATIONAL WHISTLEBLOWER DAY IN 2023
Whistleblower Network News
  • Qui Tam
  • SEC
  • CFTC
  • FCPA
  • Whistleblower Resources
  • FAQS
Subscribe
Donate
No Result
View All Result
Whistleblower Network News
No Result
View All Result
Home News

DOJ Claims Teva Pharmaceuticals Paid Illegal Kickbacks, Artificially Inflated Price Of Drugs

Peter BriccettibyPeter Briccetti
September 11, 2020
in False Claims-Qui Tam, News
Reading Time: 3 mins read
DOJ Claims Teva Pharmaceuticals Paid Illegal Kickbacks, Artificially Inflated Price Of Drugs

Medicine and healtcare costs

Share on TwitterShare on FacebookShare on LinkedInEmail

The U.S. government filed a False Claims Act case against Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. (Teva), claiming that the company illegally financed copays through supposedly independent foundations to artificially inflate the cost of one of their drugs by over 300%. The drug, Copaxone, is used to slow the progression of multiple sclerosis. Many people who require the drug, use government medical programs like Medicare and Medicaid to pay for a large portion of the price of Copaxone, as it is prohibitively expensive.

Since 2007, Teva has increased the annual cost of Copaxone from $17,000 to around $73,000 in 2015. Copays are the primary check that keeps drug companies from inflating the price of essential drugs and charging Medicare and Medicaid for the balance. Mandating that patients pay at least a percentage of the drug’s total price, keeps prices down, and inhibits fraudulent inflation. The government alleges that Teva paid kickbacks to charitable foundations to get them to pay for copays so that Teva could charge any price it wanted for the drug.

The government alleges that Teva referred all patients, who needed to pay copays for Copaxone, to Advanced Care Scripts Inc. (ACS). ACS allegedly had an agreement with Teva to refer patients to either The Assistance Fund (TAF) or The Chronic Disease Fund (CDF) for help with their copays. ACS then allegedly reported to Teva how much it would need to pay TAF or CDF to cover the patients’ copays. An operation like the one described in the filing would violate the False Claims Act’s anti-kickback statute of the False Claims Act.

Support Whistleblower Network News

When companies create illegal ways to get around common-sense government regulation of essential drug prices, it undermines the integrity of the medical system and puts many patients entirely at the mercy of Medicare and Medicaid. Many essential drugs are already prohibitively expensive for Americans with genetic disorders or chronic illnesses. Pharmaceutical companies further inflating prices to increase their profit margin is fraudulent and dangerous.

The scheme the government alleges that Teva operated is similar to one that the government recently settled for over $600 million with the national branch of Novartis, another massive pharmaceutical company. Novartis was also allegedly funneling money through front foundations to pay for otherwise unaffordable copays.

In the Novartis case, a whistleblower, or relator, stepped forward and reported the scheme to the government. Although the Department of Justice has not mentioned a whistleblower in the Teva case at this time, there may be a relator providing evidence. In cases like the one against Teva, a potential relator is eligible to receive 15 to 30% of the total funds recovered by the government.

Read the Department of Justice press release here.

Tags: qui tam whistleblowers
Previous Post

World Bank Omits Whistleblower Provisions and Protections in COVID-19 Anti-Corruption Efforts

Next Post

Representative Wild Becomes 85th Congressperson to Cosponsor Wildlife Crime Whistleblower Bill

Peter Briccetti

Peter Briccetti

Peter Briccetti is a contributing editor with Whistleblower Network News. He writes about breaking whistleblower news, and False Claims Act whistleblowers, FCPA whistleblowers, and tax fraud whistleblowers. Peter is a graduate of Hamilton College with a degree in History and an interest in politics and anti-corruption law. At Hamilton, he wrote for the Hamilton College Spectator as an editor and contributor.

Next Post
CFTC Award Fund

Representative Wild Becomes 85th Congressperson to Cosponsor Wildlife Crime Whistleblower Bill

Please login to join discussion

Receive Daily Alerts

Subscribe to receive daily breaking news and legislative developments sent to your inbox.

  • This field is for validation purposes and should be left unchanged.

Most Popular

US Attorneys Reflect on UK’s Whistleblowing Awareness Week

OSHA Highlights Railroad Worker Whistleblower Protections in Wake of Train Derailments

AML Whistleblower Law Could Shift the Way DOJ Handles Whistleblowers

Two Powerful Women Whistleblower Pairs to Learn From This Women’s History Month

WNN Exclusive Interview with Social Security Whistleblowers Sarah Carver and Jennifer Griffith — Part 2

Change the Culture, Make National Whistleblower Day Permanent

Whistleblower Poll

Whistleblower Poll
Whistleblower Poll

Exclusive Marist Poll: Overwhelming Public Support Among Likely Voters For Increased Whistleblower Protections

byGeoff Schweller
October 6, 2020

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

STAY INFORMED.
Subscribe to receive breaking whistleblower updates.

  • This field is for validation purposes and should be left unchanged.

About Us

  • About
  • Contact Us
  • Donate
  • Careers

Subscribe

  • Daily Mail
  • Follow us on Twitter
  • YouTube Channel

Contribute

  • Letter to the Editor
  • Submission Guidelines
  • Reprint Guidelines

Your Experience

  • Accessibility Statement
  • Privacy Policy
  • Terms of Use

Help

  • The Whistleblowers Handbook
  • Frequently Asked Questions
  • Advertise
Whistleblower Network News

Whistleblower Network News is an independent online newspaper providing our readers with up-to-date information on whistleblowing. Our goal is to be the best source of information on important qui tam, anti-corruption, compliance, and whistleblower law developments. 

Submit an Article

Copyright © 2021, Whistleblower Network News. All Rights Reserved.

This Newspaper/Web Site is made available by the publisher for educational purposes only as well as to give you general information and a general understanding of the law, not to provide specific legal advice. By using this website, you understand that there is no attorney-client relationship between you and the Newspaper/Web Site publisher. The Newspaper/Web Site should not be used as a substitute for competent legal advice from a licensed professional attorney in your state.

SIGN THE PETITION FOR NATIONAL WHISTLEBLOWER DAY IN 2023
No Result
View All Result
  • Exclusives
  • Government
    • False Claims-Qui Tam
    • Federal Employees
    • Intelligence
  • Corporate
    • CFTC & Commodities
    • Dodd-Frank
    • IRS & Tax
    • SEC & Securities
  • Features
  • Legislation
  • International
    • Foreign Corruption
  • Rewards
  • Whistleblower of the Week
  • Environment & Climate
  • Opinion
  • Editorial
  • Employment
    • Sarbanes-Oxley Whistleblowers
    • Retaliation
    • OSHA
  • Media
    • Podcasts
    • Videos
    • Webinars
    • National Whistleblower Day
  • Whistleblower Poll
  • Whistleblower Resources
    • Frequently Asked Questions
    • Resources for Locating An Attorney
    • The New Whistleblowers Handbook
  • National Whistleblower Day ’23

Copyright © 2020, Whistleblower Network News. All Rights Reserved.

Become a Whistleblower Network News Subscriber

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Subscribe to WNN

Retrieve your password

Please enter your username or email address to reset your password.

Subscribe to WNN

Add New Playlist

Go to mobile version